Effect of ligustrazine on experimental ischemic retina diseases

Juan Bu,Jian-Jun Yang,Jing Li,Le-Jin Wang,Wan-Rong Jin
DOI: https://doi.org/10.3969/j.issn.1672-5123.2009.02.017
IF: 1.645
2009-01-01
International Journal of Ophthalmology
Abstract:AIM: To investigate the effect of ligustrazine on animals with ischemic retina diseases which were induced by injection of endothlin-1 to vitreous. ·METHODS: ET-1 (10-6 mol/L, 10uL) was injected into the posterior vitreous of rabbit eyes to establish the animal model of ischemic retina diseases. Treatment group (n=15) received ligustrazine (20mg/kg, iv, qd), normal saline was given to control group (n=15) equivalently. At 7 days postoperatively, the content of flash electroretinogram (F-ERG), flash visual evoked potentials (F-VEP), fluorescence fundus angiography (FFA) and retinal cyclic nucleotide (cAMP ,cGMP) in two groups were detected respectively. ·RESULTS: Two days after injection of ET-1 in the posterior vitreous, significantly decreased amplitude of P (VEP) and a, b (ERG) wave (P<0.05) and the prolongation of latency in VEP (P<0.01) were found. The fundus results confirmed by FFA that showed hypofluorescence at early stage and hyperfluorescence later in optic nerve head, contractile vascular and edematous retina in rabbits received ET-1 compared with normal. The application of ligustrazine significantly reversed these changes compared with those treated with the drug vehicle only. ·CONCLUSION: Early application of ligustrazine can significantly ameliorate the signs of ischemic retina diseases. These effects suggest that ligustrazine is a potential therapeutic agent for using in the treatment of ischemic retina diseases.
What problem does this paper attempt to address?